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ABSTRACT 22
Human astroviruses (HAstVs) cause severe diarrhea and represent an important health 23 problem in children under two years of age. Despite their medical importance, the study 24 of these pathogens has been neglected. To better understand the astrovirus antigenic 25 structure and the basis of protective immunity, in this work we produced a panel of 26 neutralizing monoclonal antibodies (Nt-MAbs) to HAstV serotypes 1, 2, and 8, and 27 identified the mutations that allow the viruses to escape neutralization. We first tested 28 the capacity of the recombinant HAstV capsid core and spike domains to elicit Nt-Ab. 29
Hyperimmunization of animals with the two domains showed that although both 30 induced a potent immune response, only the spike was able to elicit antibodies with 31 neutralizing activity. Based on this finding, we used a mixture of the recombinant spike 32 domains belonging to the three HAstV serotypes to immunize mice. Five Nt-MAbs were 33 isolated and characterized; all of them were serotype-specific, two were directed to 34
HAstV-1, one to HAstV-2, and two to HAstV-8. These antibodies were used to select 35 single and double neutralization-escape variant viruses, and determination of the amino 36 acid changes that allow the viruses to escape neutralization permitted us to define the 37 existence of four potentially independent neutralization epitopes on the HAstV capsid. 38
These studies provide the basis for development of subunit vaccines that induce 39 neutralizing antibodies, and tools to explore the possibility to develop a specific 40 antibody therapy for astrovirus disease. Our results also establish a platform to advance 41 our knowledge on HAstV cell binding and entry. 42
43
Introduction 57
Human astroviruses (HAstVs) are common etiological agents of acute gastroenteritis in 58 children, the elderly, and immunocompromised patients (1-3). They are estimated to be 59 responsible for 2 to 9% acute, nonbacterial childhood diarrhea (4). Recently, the 60 epidemiology of HAstV in community settings of 8 low-and middle-income countries 61 with high prevalence of diarrhea and undernutrition was reported (5); the prevalence of 62
HAstV in diarrheal stools was 5.6%, and remarkably, its severity exceeded all 63 enteropathogens tested, except rotavirus. In a related study, norovirus GII, rotavirus, 64 and astrovirus exhibited the highest attributable burdens of diarrhea in the first two 65 years of life (6). These studies show that HAstV is an overlooked cause of diarrhea 66 among vulnerable children worldwide, and they highlight the need for future research 67 as well as the importance of this virus as a target for vaccine development (5, 6) . 68
HAstVs are classified into 8 classical serotypes (HAstV-1 to -8) associated with 69 acute gastroenteritis, however novel HAstV strains have been recently described and 70 are also associated with neurological disease, including meningitis and encephalitis in 71 immunocompromised patients (4). HAstVs are small, nonenveloped viruses with a 72 single-stranded positive-sense RNA genome of about 6.8 kb comprising three open 73 reading frames (ORFs). ORF2 encodes a capsid precursor structural polyprotein of about 74 90 kDa that self-assembles intracellularly and is processed by caspases to produce a 75 virus particle formed by a 70 kDa protein (VP70) (7). This immature particle egresses the 76 cell and is further processed by extracellular proteases; in vitro, the treatment of this 77 particle with trypsin yields a mature infectious virus that, in HAstV-8, contains three 78 protein species of approximately 34 (VP34), 27 (VP27), and 25 (VP25) kDa (7), although 79 it has been recently shown that only VP34 and VP27 are relevant for HAstV-8 infectivity 80
Cryo-electron microscopy of mature HAstV virions reveals particles of 44 nm 82 comprised of a T=3 icosahedral shell and 30 globular spikes (9). The crystal structures of 83 both VP34 (10, 11) and VP25 (11-14) have been recently determined; VP34 folds into a 84 domain that constitutes the shell of the virus capsid (core domain), while VP27/VP25 85 form dimeric capsid spikes (spike domain). VP34 is derived from the highly conserved N-86 terminal region of VP70, while VP27/VP25, which differ only at their amino terminus, 87 are derived from the hypervariable region of VP70 (15). Despite important advances in 88 the structural characterization of the HAstV particle, the functional sites on the virus 89 capsid, including the location of the receptor-binding site and the antigenic 90 determinants where neutralizing antibodies bind, have been poorly characterized. Only 91 one neutralizing antibody epitope, located on the capsid spike domain, has previously 92 been defined by X-ray crystallography (12). 93
To better understand the astrovirus antigenic structure and the basis of 94 protective immunity, in this work we produced neutralizing monoclonal antibodies (Nt-95 MAbs) to HAstV serotypes 1, 2, and 8 and identified the mutations that allow variant 96 viruses to escape neutralization. This allowed us to define the existence of four 97 potentially independent neutralization epitopes on the HAstV capsid. These studies 98 provide the basis for the development of subunit vaccines to induce neutralizing 99 antibodies and tools to explore the possibility to develop a specific antibody therapy for 100 6 astrovirus disease. Our results also establish a platform to advance our knowledge on 101
HAstV cell binding and entry. 102
103
RESULTS
104
The HAstV capsid spike but not the capsid core domain induces neutralizing 105
antibodies. To identify the neutralization epitopes on the HAstV capsid, we first 106 evaluated the capacity of the core and spike domains to induce total (ELISA) and 107 neutralizing antibodies. These two structural domains of the virus can be produced in E. 108 coli in a soluble and correctly folded form (10-14). Rabbits and mice were immunized 109 with either the purified, recombinant core or the spike domains of HAstV-1 (core1 or 110 spike1). As expected, both domains were immunogenic and induced a robust antibody 111 response (Fig. 1A) . We then tested the capacity of the polyclonal sera directed to either 112 domain to neutralize the infectivity of HAstV-1. The core1 did not induce a detectable 113 level of neutralizing antibodies to either HAstV-1, HAstV-2 or HAstV-8 (Fig. 1B) , while the 114 spike1 domain induced a high (>1/50,000) neutralizing response that was specific for 115
HAstV-1 (Fig. 1B) 
116
Of interest, despite the fact that the anti-spike1 mouse polyclonal serum (both 117 rabbit and mice sera behaved equally in all assays tested) was specific for HAstV-1 by 118 neutralization, it also recognized the heterologous capsid spikes of HAstV-2 and -8 119 (spike2 and spike8) by ELISA, although about 50 to 100 times less efficiently ( Fig. 2A) . 120
The anti-spike2 antibodies (see Material and Methods) interacted also weaker with 121 spikes 1 and 8 (Fig. 2B) . On the other hand, the anti-spike8 serum recognized better the 122 spike1 (with about 5 to 10-fold difference) than the spike2, which was bound about 100 123 times less efficiently (Fig. 2C) . In turn, the anti-core1 polyclonal serum cross-reacted 124 efficiently with the core domain of both HAstV-2 and HAstV-8 by Western blot, and also 125 recognized cells infected with HAstV serotypes 1, 2, or 8, by both immunocytochemistry 126 and immunofluorescence (Figs. 2D and 2E) . 127
128
Isolation and serotype-specificity of neutralizing monoclonal antibodies. Given that the 129 spike was the only domain that induced neutralizing antibodies, we used it to immunize 130 mice to generate Nt-MAbs. Since we were interested in isolating cross-reactive, 131
heterotypic Nt-MAbs, we immunized mice with a mixture of spike domains of HAstV 132 serotypes 1, 2, and 8, following the immunization scheme described in Material and 133
Methods. The primary screening for hybridomas secreting astrovirus-specific MAbs was 134 carried out by ELISA, using as antigens the individual spike proteins from the three 135 different HAstV serotypes. We selected 54 positives hybridomas from 480 wells initially 136 screened; twenty-one for spike1, one for spike 2, and sixteen for spike8. Thirteen were 137 cross-reactive with at least 2 serotypes, and three recognized the spike domain of the 3 138 serotypes. Twenty-two of these hybridomas were further screened by a neutralization 139 assay. Twelve of these MAbs had neutralizing activity, and five of them that grew stably 140 were cloned and expanded for further analysis. Of these, two Nt-MAbs were directed to 141
HAstV-1 (MAbs 3B4 and 3H4), one to HAstV-2 (MAb 4B6), and two to HAstV-8 (MAbs 142 2D9 and 3E8). All five Nt-MAbs were serotype-specific by ELISA (not shown) and8 neutralization (Fig. 3) , and also specifically recognized their antigen by 144 immunocytochemistry and immunofluorescence in Caco-2 infected cells (not shown). 145
In general, all selected MAbs neutralized the cognate virus to high titers. Those 146 specific for HAstV-1 had a neutralization titer higher than 1/10,000, which was slightly 147 lower than the neutralization titer achieved with the hyperimmune polyclonal serum to 148 spike1 ( 159 dilution of the ascites fluid (Fig. 4) , with exception of the escape variant for MAb 2D9 160 (vHAstV-8/2D9), which was slightly neutralized by MAb 2D9 (titer 5 x 10 -3 ) (Fig. 4D) , 161 although more than 1,000-fold less efficiently as compared to the wt HAstV-8 virus (titer 162 8 x 10 -6 ) (see Fig. 4D ). On the other hand, all escape variants were still efficiently 163 neutralized by the corresponding hyperimmune anti-spike serum (Fig. 4) , indicating the 164 existence of more than one neutralization epitope on the spike domain of HAstV. 165
When cross-neutralization of escape variants of the same HAstV serotype were 166 tested, i.e., neutralization of vHAstV-1/3B4 by MAb 3H4 and neutralization of vHAstV-167 1/3H4 by MAb 3B4, an efficient inhibition of infectivity was still observed, suggesting 168 that the these two MAbs recognize two different epitopes on the virus (Figs. 4A and 4B) . 169
Similar results were obtained when HAstV-8 neutralization-escape variants vHAstV-170 8/2D9 and vHAstV-8/3E8 were evaluated for inhibition by MAbs 2D9 and 3E8, since they 171 were neutralized with titers higher than 10 -6 by the "non-homologous" MAb, suggesting 172 again that these MAbs might interact with two different antigenic determinants on the 173
HAstV-8 capsid (Figs. 4D and 4E) . Of interest, it was also possible to isolate HAstV-1 174 variants that were highly resistant to neutralization by both MAbs 3B4 and 3H4, as well 175
as HAstV-8 double-escape variants that were resistant to inhibition by both 2D9 and 3E8 176 MAbs (Fig. 5) , showing the resilience of the virus to withstand mutations in more than 177 one site in order to escape antibody neutralization. Even more, the double-escape 178 variants were still efficiently neutralized by the hyperimmune polyclonal sera, 179
suggesting that there are more than two neutralizing antigenic regions on the virus. 180
Identification of the amino acid changes that confer viruses resistance to 182
neutralization by monoclonal antibodies. To understand the localization of the 183 neutralization epitopes, we sequenced the genome region encoding the spike of the 184 virus escape variants and identified amino acids changes that confer virus resistance to 185 the Nt-MAbs. A single amino acid change was identified in the spike sequence of each 186 single variant, with exception of vHAstV-2/4B6 that had two contiguous amino acids 187 changed (Table 2 , Fig. 6A ). The identified neutralization-escape mutations were then 188 mapped onto the crystal structure of the spike1 domain (11); all of the mutated amino 189 acids were located on the surface of the spike (Fig. 6B ). In agreement with the results 190 described above that suggest that the MAbs to HAstV-1 recognize different antigenic 191 sites (Fig. 4) , the amino acid residues that confer HAstV-1 resistance to neutralization by 192 MAbs 3H4 and 3B4 were located into two very different regions of the spike (Fig. 6B , 193 Table 2 ). A K504E change, located in loop 2, on the inferior/lateral region of the spike, 194 conferred resistance to MAb 3H4, while the S560P mutation that results in the loss of 195 neutralization by MAb 3B4, is located on the top of the spike in the middle of the long 196 loop 3 that extends over the top, adjacent to the monomer-monomer contact in the 197 spike, away from the K504E amino acid change. 198
The escape of neutralization of HAstV-2 by MAb 4B6 was the consequence of 199 two contiguous amino acid changes (D564E, N565D) located in loop 3, on the top of the 200 spike, very close to the amino acid that defines the resistance of HAstV-1 to MAb 3B4 201 Table 2 ). In the case of HAstV-8, the mutations that confer resistance to MAbs 202 3E8 and 2D9 were found to map on different sides of the spike, opposite to the dimeric 203 subunit. These changes, Y464H for MAb 3E8 and D597Y for MAb 2D9 ( (Table 2) . A similar finding was obtained when the double-escape variants of 210
HAstV-8 were characterized (Table 2) . 211
212
DISCUSSION 213
To gain insight into the antigenic sites of the HAstV capsid, Nt-MAbs directed to 214 serotypes 1, 2, and 8 were produced, and the sites of amino acid mutations that allow 215 the viruses to escape neutralization were mapped onto the virus capsid spike. Only two 216 reports published over twenty years ago have described the isolation of Nt-MAbs to 217
HAstV. In the first study, one MAb specific for HAstV-2 (MAb PL-2) was isolated (16) . In 218 the second work, three Nt-MAbs targeting HAstV-1 were reported (17) . Despite the fact 219 that in those studies purified virus was used as immunogen, all neutralizing MAbs 220 isolated were directed to the spike domain, in agreement with our findings that the 221 spike, but not the core domain is able to induce Nt-MAbs. Also, the crystal structure of 222 the HAstV-2 spike bound to the Fab fragment of MAb PL-2 was recently reported (12) , 223 confirming the spike domain as a target for neutralizing antibodies. In the work by Bass 224 et al. (17) , the three MAbs to HAstV-1 were found to be topographically in close 225 proximity, by a competition ELISA. All four Nt-MAbs previously reported were able to 226 prevent the attachment of the virus particles to Caco-2 cells, suggesting that the spike 227 domain also contains the receptor-binding site of the virion. These results indicate that a 228 subunit vaccine should focus on the spike domain as the main immunogen to induce a 229 potential protective antibody response. 230
Of interest, two of the Nt-MAb reported by Bass et al (17) neutralized more than 231 one serotype, with one of them being broadly neutralizing to all seven HAstV tested, 232 although this MAb was of IgM isotype and it probably was of low affinity. None of these 233
MAbs are currently available. In this regard, we found that about 1 out of 4 of the 234 initially positive hybridomas neutralized more than one serotype, indicating again the 235 existence of cross-neutralizing epitopes in the spike domain. It cannot be discarded, 236
however, that a proportion of the cross-reacting hybridomas were the result of a 237 mixture of two or more independent hybridoma cell clones having different serotype 238 specificity. Regardless of this fact, the cross-neutralization epitopes do not seem to be 239 immunodominant, at least in mice, since the anti-spike1 hyperimmune polyclonal serum 240 was serotype-specific by neutralization and recognized about 10-fold less efficiently the 241
HAstV-2 and HAstV-8 spikes by ELISA. 242
It is important to note that the infectivity of the neutralization-escape variants 243 was blocked by the hyperimmune serum to the corresponding spike to a titer similar to 244 that found for the wild-type virus. It would be interesting to test whether the 245 neutralization-escape variants are also efficiently neutralized or not by convalescent 246 sera from patients naturally infected with astrovirus, since in the case of rotavirus it has 247 been shown that marked differences can characterize the immune responses to 248 parenteral hyperimmunization in comparison with responses to intestinal infection (18). 249
Analysis of the structure of the recombinant HAstV-2 spike domain bound to scFv 250 PL-2 (12) showed that this neutralizing MAb recognizes a quaternary epitope on each 251 side of the dimeric capsid spike, and a deletion of three amino acids (aa [460] [461] [462] in 252 loop1 abolished the binding of PL-2. The location of the MAb3E8 escape mutation in 253 loop1 suggests that MAb 3E8 (anti-HAstV-8) may recognize an epitope that overlaps 254 with the MAb PL-2 (anti-HAstV-2), suggesting in turn that different HAstV serotypes may 255 share neutralization epitopes on the spike domain. In this regard, the escape mutations 256 that allow HAstV-1 and HAstV-2 to escape neutralization by MAbs 3B4 and 4B6, 257 respectively, are only 4 amino acids apart in loop 3 (see Table 2 and Fig. 6 ), suggesting 258 again that potentially this could be the same epitope shared by these two HAstV 259 serotypes. On the other hand, MAbs 3H4 and 2D9, localized in loops 2 and 4, 260 respectively, seem to define two new independent epitopes on the astrovirus capsid, Of interest, all of the neutralizing escape mutations identified in this work, with 273 exception of K504E (vHAstV-1/3H4), map close (only between 5 and 10 amino acids 274 away) to the conserved amino acids that have been proposed to line the P and S sites, 275 which are potentially functional sites identified in the HAstV-8 spike (13). It is likely that 276 the footprint of the MAbs that recognized these epitopes overlaps the proposed 277 functional P and S sites. Also, the footprint of MAb PL-2 on the HAstV2 spike was 278 described to overlap four conserved amino acid regions, and to block the binding of the 279 recombinant spike2 to Caco-2 cells, suggesting that this MAb could also inhibit the 280 attachment of the virus to the cell surface through interfering the interaction of the 281 virus with the cell receptor (12). 282
When screening the Genbank database to look for wildtype viruses that could 283 have the mutations identified in our neutralization escape mutants, we found 24, 9, and 284 3 complete spike sequences that were annotated as HAstV serotypes 1, 2, or 8, 285
respectively. None of the 24 HAstV-1 strains found had a change at Ser-560. In contrast 286 the Lys-504 was only present in only one of the 24 viruses; one additional virus had a 287
Pro in that position and twenty-two showed a Gln. Regarding HAstV-2, four of the spike 288 sequences found showed Asp-Asn-Asn at amino acid positions 564-566, as the wildtype 289 HAstV-2 virus characterized in this work, while five had a deletion of one of the two Asn 290 residues. Finally, the three additional serotype 8 HAstV strains had the same amino 291 acids as the parental Yuc8 virus at the amino acid residue positions where escape 292 mutations to MAbs 2D9 and 3E8 were mapped. Overall, the finding of amino acid 293 differences at some of the positions that allow our variant viruses to escape 294 neutralization by the selected MAbs has to be interpreted cautiously, and cannot be 295 ascribed to have occurred as the consequence of selective pressure in humans, since our 296
MAbs recognizes a mouse epitope, which could or could not be immunogenic in 297 humans. Whether these amino acid changes actually allow them to escape 298 neutralization by the MAbs described in this study needs to be determined 299 Work in progress in our labs is directed to define the mechanism of 300 neutralization of the antibodies characterized in this work, and to use structural biology 301 to define the antigenic sites of the Nt-MAbs described in this study. Altogether, our 302 results advance our knowledge on the antigenic structure of HAstVs, the basis of HAstV 303 neutralization, and the functional sites relevant for virus entry, providing a basis for the 304 development of vaccines and therapeutic measures against astrovirus disease. 305
306
MATERIAL AND METHODS 307
Cells and viruses. Caco-2 cells, clone C2Bbe1 (ATCC), were propagated in Dulbecco´s 308
modified Eagle´s medium-High Glucose (DMEM-HG) (Sigma) supplemented with non-309 essential amino acids (Gibco) and 15% fetal bovine serum (FBS) (Cansera) in a 10% CO 2 310 atmosphere at 37°C. HAstV serotype 1 (HAstV-1-RIVMb) was obtained from Susana Guix 311 (Department de Microbiologia, Facultat de Biologia, Universitat de Barcelona, HAstV 312 serotype 2 strain Oxford (HAstV-2-Oxford) was obtained from J.B. Kurtz (Dept. of 313 Virology, John Radcliffe Hospital, Oxford, UK). HAstV serotype 8 strain Yuc8 was isolated 314 in our laboratory. All viral strains were activated with trypsin and grown as described 315
(19).
HAstV-1 CP core production. cDNA corresponding to HAstV-1 capsid protein residues 80 318 to 429 (accession number AAC34717.1) was cloned into pET52b in frame with a C-319 terminal thrombin cleavage site and a 10-histidine purification tag sequence. The 320 plasmid was transformed into Escherichia coli strain BL21(DE3)pLysS, and HAstV-1 CP 321 core expression was induced with 1 mM IPTG (isopropyl-β-d-thiogalactopyranoside) at 322 18°C for 16 h. E. coli cells were lysed by ultrasonication in 20 mM Tris, pH 7.5, 1 M NaCl, 323 5% (vol/vol) glycerol, 1 mM dithiothreitol (DTT), and 20 mM imidazole containing 2 μM 324 MgCl 2 , 1,250 U Benzonase (Millipore), and 1× protease inhibitor cocktail Set V EDTA-325
Free (Millipore). The HAstV-1 CP core was purified from soluble lysates by HisTrap 326 metal-affinity chromatography. The HAstV-1 CP core was further purified by size-327 exclusion chromatography on a Superdex 75 column in 20 mM phosphate buffer, pH 328 7.6, 1 M NaCl, and 5% (vol/vol) glycerol. 329 330
HAstV spike production. Synthetic genes codon optimized for Escherichia coli encoding 331
HAstV-2-Oxford amino acids 431 to 674 capsid spike (GenBank accession number 332 KY964327), HAstV-1 capsid protein residues 429 to 645 (accession number AAC34717.1), 333 or HAstV-8 CP spike amino acids 429 to 647 (UniProtKB entry Q9IFX1). To make spike 334 expression plasmids, genes were cloned into pET52b (Addgene) in frame with a C-335 terminal thrombin cleavage site and a 10-histidine purification tag. All plasmids were 336 verified by DNA sequencing. Plasmids were transformed into E. coli strain BL21(DE3), 337 and protein production was induced with 1 mM IPTG at 18°C for 16 h. E. coli cells were 338 lysed by ultrasonication in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, and 20 mM imidazole 339 HAstV-2 capsid gene (accession number L06802.1), were used for HAstV-1-RIVMb and 400
HAstV-2-Oxford strains, and primer HAstV-8Up, 5'-CAGTTTACACAGATGAATCA-3', 401 corresponding to nucleotides 5531-5551 of the HAstV-8 strain Yuc8 (accession number 402 AF260508.1), for HAstV-8-Yuc8. The PCR product was purified using the DNA clean and 403
Concentrator-5 kit (Zymo Research) and sequenced using the Sanger chemistry in the 404 sequencing facility of the Instituto de Biotecnología, UNAM. The sequences of the 405 amplified PCR products were deposited in GenBank, with accession numbers MH763691 406 (HAstV-1), KY964327 (HAstV-2), and MH763692 (HAstV-8). 407
408
Isolation of neutralization escape variants. For selection of escape variants, we 409 incubated viral lysates (with at least 1 X 10 7 ffu/ml) with the appropriate mAb at 410 1:1,000-1:100 dilution of the ascites fluid for 1 h at room temperature, then the mix was 411 used to infect CaCo-2 monolayers grown in 6-well plates for 1 h at 37°C, and the 412 unbound virus was removed by washing three times. The cell monolayers were 413 incubated at 37°C by 48 to 72 hpi in the presence of trypsin (5 µg/ml), tetracycline (1 414 µg/ml), and the corresponding mAb diluted 1:1,000. Viral lysates were then prepared by 415 three cycles of freeze-thawing, and the procedure was repeated for at least three times 416 before confirming the phenotype. The phenotype of the variant viruses was evaluated 417 by neutralization assays, and the selection was repeated until detection of the 418 neutralization escape variant (this usually took 4 to 5 passages in the presence of the Nt-419 MAb). The double-escape variants were selected as described above, but starting with 420 the single variant, instead of the wt virus. Conserved, similar, and nonconserved amino acids are colored red, pink, and black, 548 respectively. The amino acid residues that changed in the variants that escaped 549 neutralization by MAbs 3H4 and 3B4 to HAstV-1, 4B6 to HAstV-2, and 3E8 and 2D9 to 550
HAstV-8, are indicated with green, gold, and blue arrows, respectively. B) Spike1 551 structure shown from the top and one side. One half of the dimer is gray, and the other 552 half is white. The positions of the mutations that confer escape to neutralization by the 553 various monoclonal antibodies are colored green for HAstV-1, gold for HAstV-2, and blue 554 to HAstV-8. The mutations are shown in only one protomer in the dimer. 555 28 TABLES 558 
